Emergency anthrax drug study launched for bioterror attack scenarios

This study aims to collect real-world data on how well the drug raxibacumab works and how safe it is for treating people who develop symptomatic inhalational anthrax after a mass exposure event, such as a bioterror attack. It will enroll up to 100 patients of all ages who receive the drug from emergency stockpiles as part of their standard medical care. The goal is to better understand the drug's benefits for survival and its safety profile to inform future treatment decisions during such emergencies.